Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prospective and Retrospective Cohort Study to Find New Prognostic Factors and Therapeutic Targets in Patients With Newly Diagnosed or Relapsed Malignant Hematologic Disorder Excluding Acute Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02330718
Recruitment Status : Recruiting
First Posted : January 5, 2015
Last Update Posted : February 22, 2019
Sponsor:
Information provided by (Responsible Party):
Yonsei University

Brief Summary:
The purpose of this study is to elucidate the factors which are associated with the diagnosis and predict prognosis and therapeutic targets by collecting specimens of tissue sample, peripheral blood, and bone marrow aspirates at the time of diagnosis or relapse/refractory in patients with malignant hematologic disorders except acute leukemia. This study is eligible for patients who are diagnosed with malignant hematologic disorders except acute leukemia or who will have diagnostic procedure with suspicion of having hematologic malignancy. Prospective cohort is for patients who are not in treatment for hematologic malignancy. Retrospective cohort is for patients who are diagnosed and in treatment.

Condition or disease Intervention/treatment
Malignant Hematologic Disorder Other: No intervention

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 1500 participants
Observational Model: Cohort
Time Perspective: Other
Target Follow-Up Duration: 5 Years
Study Start Date : May 2014
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : April 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Blood Disorders




Primary Outcome Measures :
  1. the number of patients with malignant hematologic disorders to examine the new prognostic factors and therapeutic targets [ Time Frame: 5 years ]

Biospecimen Retention:   Samples Without DNA
peripheral blood and bone marrow aspirates have been collected and stored for the study


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with newly diagnosed or relapsed malignant hematologic disorders except acute leukemia
Criteria

Inclusion Criteria:

  • The patients with malignant hematologic disorders except acute leukemia who are diagnosed pathologically according to the revised 2008 WHO classification of tumours of haematopoietic and lymphoid tissue or who will have diagnostic procedure with suspicion of having hematologic malignancy.
  • Any gender and age ≥ 19 years
  • Written informed consent
  • Diagnosed after 2005-01-01 in retrospective cohort group.

Exclusion Criteria:

  • Patients who cannot understand or disagree the informed consent
  • Patients who diagnosed with acute leukemia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02330718


Locations
Layout table for location information
Korea, Republic of
Severance Hospital Recruiting
Seoul, Korea, Republic of, 120-752
Contact: Jin-Seok Kim, MD, Ph.D    82-2-2228-1972      
Sponsors and Collaborators
Yonsei University

Additional Information:

Layout table for additonal information
Responsible Party: Yonsei University
ClinicalTrials.gov Identifier: NCT02330718     History of Changes
Other Study ID Numbers: 4-2014-0236
First Posted: January 5, 2015    Key Record Dates
Last Update Posted: February 22, 2019
Last Verified: February 2019

Additional relevant MeSH terms:
Layout table for MeSH terms
Hematologic Diseases